FOSTER CITY, Calif. / Dec 20, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m. Pacific Time The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation. About Gilead...Read more
WARSAW, Ind., Dec. 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT (11:15 a.m. ET). A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The...Read more
SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will present the latest company updates at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Tuesday, January 14, 2025, at 3:45 p.m. PT. Investors and other interested parties can access the...Read more
CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 9:00 a.m. PT in San Francisco. A live...Read more
JERSEY CITY, N.J. / Dec 19, 2024 / Business Wire / Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, 2025, at 3:45 p.m. PT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the...Read more
SOUTH SAN FRANCISCO / Dec 19, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. Pacific Time in San Francisco, California. The...Read more
SAN DIEGO / Dec 19, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time. A live webcast of Acadia’s presentation will be accessible on the...Read more
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT. A live...Read more
WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare...Read more
Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal...Read more
SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare conference on Thursday, January 16, 2025, at 10:30 AM - 11:10 AM. A live and archived webcast will be accessible on Skye’s...Read more
Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities Completed additional private placement with Gilead for purchase of remaining equity investment in connection with XTX301 partnership WALTHAM, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage...Read more
VICTORIA, British Columbia / Dec 19, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, in Atlantic City, NJ. IPA’s management...Read more
DEERFIELD, Ill. / Dec 18, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. José (Joe) E. Almeida, Baxter's chair, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for...Read more
CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET). A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint...Read more
PLYMOUTH MEETING, Pa., Dec. 18, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Jeffrey M. Dayno, M.D., President and Chief Executive Officer, is scheduled to present at the conference on Wednesday, January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET. A webcast of...Read more
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15,...Read more
MENLO PARK, Calif., Dec. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15 at 9:00 a.m. PT. Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at...Read more
CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2024 at 7:30 AM PST. Among other business updates, Mr. Butler will discuss the Vafseo®...Read more
MOUNTAIN VIEW, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference at 4:30pm PT (7:30pm ET) on Wednesday, January 15, 2025, in San Francisco, CA. Management will also host investor meetings during the conference. The...Read more
VALENCIA, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025, at 9:00 a.m. Pacific Time. A live audio webcast of the...Read more
JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that an abstract entitled “Interim analysis of feasibility, safety, and tumor control in two first-in-human trials of a novel alpha-emitting radionuclide for pancreatic adenocarcinoma,” submitted by principal investigators...Read more
Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent...Read more
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical...Read more
Presentations will showcase new data reinforcing BOT/BAL’s potential across different lines of treatment in colorectal cancer, including the neoadjuvant setting LEXINGTON, Mass. / Dec 18, 2024 / Business Wire / Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 antibody) at the upcoming American...Read more
SAN DIEGO and CALGARY, AB, Dec. 18, 2024 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO)...Read more
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced a presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers (ASCO...Read more
Presentation Topic is the Pharmacokinetics of AL001, a Lithium Salicylate/L-Proline Co-crystal, as a Potentially Beneficial Lithium Sparing Treatment for Bipolar Disorder Type 1, Alzheimer’s Disease, Major Depressive Disorder and Post-Traumatic Stress Disorder ATLANTA / Dec 18, 2024 / Business Wire / Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for...Read more
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco. A live webcast will be available in the...Read more
TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at...Read more
SAN RAMON, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading medical device company, today announced it will participate at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. Al White, President and CEO, will represent the Company in a session scheduled to begin at 6:00 PM ET. A live and archived webcast of this event, where applicable, will be available by accessing the CooperCompanies’...Read more
WALTHAM, Mass. / Dec 17, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available via this page. A replay of the presentation will...Read more
WILMINGTON, Del. / Dec 17, 2024 / Business Wire / Incyte (Nasdaq: INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to...Read more
DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a business update on Tuesday, January 14, 2025, at 9:45 a.m. PST / 5:45 p.m. GMT. A live audio webcast of the presentation may be accessed...Read more
CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 1:30 p.m. PT in San Francisco. A live webcast will be available in the investor section of the...Read more
BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 at 3:45 p.m....Read more
SAN CARLOS, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next-generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, California. Gina Chapman, President and Chief Executive...Read more
WATERTOWN, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday,...Read more
BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis tomorrow, December 18, 2024. The data will be provided in a press release and presented during a conference call...Read more
SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place January 13 – 16,...Read more
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will attend and present the Company’s latest developments and outlook for 2025 at two upcoming investor conferences in...Read more
YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. The event will focus on EscharEx®, an innovative biologic drug in late-stage clinical development for chronic wound debridement, including the upcoming Phase III VALUE...Read more
- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer - - The company will also provide initial data from IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer, as well as IMM-1-104 monotherapy in second-line pancreatic cancer - CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immuneering...Read more
Single intrathecal dose of Rhenium (186Re) Obisbemeda delivers favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical evaluation Both single-dose and multiple-dose expansion trials planned in 2025 AUSTIN, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with...Read more
CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst will present at the 43rd Annual J.P. Morgan Healthcare Conference...Read more
STAMFORD, Conn. / Dec 16, 2024 / Business Wire / GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16 in San Francisco, CA. Management will participate in a presentation on Wednesday, January 15, 2025, at 4:30 p.m. PT. Live and archived webcasts will be available on the...Read more
CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 9:45 a.m. PT /...Read more
NEW YORK & BURLINGTON, Mass. / Dec 16, 2024 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will participate at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 at the Westin St. Francis in San Francisco, California. Joseph DeVivo, President, Chief...Read more
Presentations included a case study of the workflow for building multispecifics and the launch of OmniHub™, a bioinformatics tools platform EMERYVILLE, Calif. / Dec 16, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company’s technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego. In a presentation titled “Building...Read more
SAN DIEGO / Dec 16, 2024 / Business Wire / Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that Joseph Payne, President & Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San...Read more
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene, will present at the 43rd Annual J.P. Morgan Healthcare Conference at the Westin...Read more
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, will announce initial Cohort 1 data from the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) on...Read more
ICE3 trial results presented by ICE3 Co-Principal Investigator Dr. Kenneth Tomkovich FDA Advisory Panel voted in favor of IceCure's ProSense® cryoablation benefit-risk profile in early-stage low risk breast cancer in Nov. 2025 FDA's marketing authorization decision expected in Q1, 2025 CAESAREA, Israel, Dec. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"),...Read more
Meet with Serina’s CEO Steven A. Ledger Parkinson's disease is a progressive neurological disorder that primarily affects movement Continuous dopaminergic stimulation (CDS) has been shown to reduce the severity of motor complications (dyskinesia) in advanced Parkinson’s patients Discussion of the Serina IND candidate’s target product profile versus the current standard of care in providing CDS HUNTSVILLE, AL, Dec. 16, 2024...Read more
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS) One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS Mec-V antitumor activity observed across 9 different mKRAS variants Strong association of...Read more
WARRINGTON, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a well-received presentation highlighting the data on istaroxime from the...Read more
THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET WALTHAM, Mass. / Dec 13, 2024 / Business Wire / Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today...Read more
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon® (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for patients with early stage breast cancer...Read more
BriaCell reports influx of cancer fighting CD8+ “killer” T cell into metastatic breast cancer tumors and lymph organs turning “Cold” tumors and lymph nodes “Hot” on ImmunoPET imaging in cancer patients treated with Bria-IMT™ plus an immune checkpoint inhibitor (CPI) Imaging confirms clinical responses seen in metastatic breast cancer correlate with increase in CD8+ “killer” T Cells in lesions and lymph nodes PHILADELPHIA and...Read more
Crofelemer is the subject of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - for the rare disease indications of microvillus inclusion disease (MVID) and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of IIT proof-of-concept results potentially in Q2 2025 Virtual event 11:00 AM to 12:00 PM...Read more
Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B1 Poised to Deliver Sustainable Growth Expected Phase 3 Data Readouts in 2025 for Oveporexton (TAK-861), Zasocitinib (TAK-279) and Rusfertide (TAK-121) Regulatory Filings for Oveporexton (Narcolepsy Type 1), Zasocitinib (Psoriasis) and Rusfertide (Polycythemia Vera) on Track for Fiscal Years 2025 - 2026 Five Additional Filings Anticipated in Fiscal Years 2027 - 2029...Read more
Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original target Nomination of ZW209, a novel trispecific T cell engager, as fifth development candidate in the Company’s solid tumor portfolio Expansion into autoimmune and inflammatory diseases (AIID) and hematology oncology leverages the Company’s clinically validated Azymetric™ technology...Read more
Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025 Heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification and/or polysomy demonstrated an enhanced response to zelenectide...Read more
Drug candidate selected for ABS-201, a novel, potentially category-defining anti-PRLR antibody in development for androgenic alopecia Leading AI platform demonstrated breakthrough in successful de novo design of antibody targeting previously difficult-to-drug epitope in the HIV “caldera” region VANCOUVER, Wash. and NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation...Read more
Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1 Positively, median overall survival (OS) has not yet been reached and the 12-month OS rate is 67%, both well above historical controls Complete response rate increases to 12.9% and 16.1%, according to RECIST 1.1 and...Read more
Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrated 73.3% ORR, with 64.6% of patients achieving landmark 6-month PFS Inupadenant + carboplatin/pemetrexed safety profile was manageable and tolerable, with no...Read more
In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression levels of both the GLP-1 receptor (GLP-1R) as well as intracellular insulin. Overall results showed synergy of the combination therapy, which may allow lower doses of GLP-1-based therapies to achieve glycemic targets, potentially reducing side...Read more
SEATTLE, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced data describing the discovery of compounds that may be synergistic with (Z)-endoxifen and that could potentially be used in combinations for the...Read more
RJVA-001 was successfully delivered in large animal Yucatan pig models at low total viral dose Results confirm ability to directly target pancreas with novel delivery catheter and route of administration Local delivery of RJVA-001 achieved therapeutically relevant GLP-1 expression within pancreatic beta cells with no adverse safety effects observed Company plans to initiate first-in-human studies with RJVA-001 in first half of...Read more
Webcast on December 17 at 8:00 AM EST to feature ALX Oncology leadership and study principal investigator Alberto J. Montero, MD, MBA SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, announced that the company will...Read more
Updated Phase 1 data include a 16.3-month median recurrence-free survival (“mRFS”) and 28.9-month median overall survival (“mOS”) from full study population Strong correlation observed between mRFS and strength of T cell response Event-driven interim analysis from randomized Phase 2 trial expected in H1 2025 BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a...Read more
Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 OnTarget trial evaluating crofelemer for prophylaxis of CTD The majority of patients in the OnTarget placebo group on abemaciclib and pertuzumab-based therapies required dose reduction or elimination SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals...Read more
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder Data shows robust remission and response efficacy rates in patients taking CAPLYTA Robust improvements in anxiety symptoms were also observed in patients taking CAPLYTA as measured by the Generalized Anxiety Disorder Questionnaire...Read more
Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway PASADENA, Calif. / Dec 11, 2024 / Business Wire / Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic targeting complement factor B being developed...Read more
NEW YORK / Dec 11, 2024 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it presented encore data from its Phase 2b study of MM120 (lysergide D-tartrate or LSD), the Company’s lead product candidate in generalized anxiety disorder, at the ACNP 2024 Congress taking...Read more
Multiple well-tolerated doses with pharmacodynamic activity were identified and will be included in a planned Phase 2b study in major depressive disorder BOSTON / Dec 11, 2024 / Business Wire / PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, (“Seaport”) a clinical-stage biopharmaceutical company that is advancing...Read more
Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with a CDK4/6 inhibitor was 33.9 months MINNEAPOLIS, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced overall...Read more
CDK2-directed MGD drove deep tumor regression in preclinical models of HR-positive/HER2-negative breast cancer when combined with either a CDK4/6 inhibitor or a CDK4/6 inhibitor and endocrine therapy Potential to provide more sustained responses in a difficult-to-treat patient population, while avoiding toxicities typically associated with limited selectivity of CDK2 inhibitors BOSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) --...Read more
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen will present at the Oppenheimer Movers in Rare Disease Summit at the Westin Grand Central, New York on Thursday, December...Read more
MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing MG29-1 nuclease targeting the albumin safe harbor locus showed no evidence of translocations in primary human hepatocytes Metagenomi Adenine Base Editor (ABE) demonstrates no detectable translocations and no significant genomic base composition differences in primary T-cells EMERYVILLE, Calif., Dec. 11, 2024 (GLOBE...Read more
Data generated from Alto’s precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for patient selection An interim analysis will be conducted for the ongoing Phase 2b trial of ALTO-300 as an adjunctive...Read more
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston, MA. Entitled "Overcoming Anti-PEG...Read more
NASHUA, N.H., Dec. 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader in clinically proven AI-powered cancer detection solutions, announced today that four novel AI-driven breast cancer research abstracts have been accepted for presentation at the 2024 San Antonio Breast Cancer Symposium (SABCS), taking place from December 10-13, 2024. These clinical abstracts highlight the latest research in...Read more
BETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Financial Officer and Interim Chief Executive Officer of Gain, will give a corporate presentation at Biotech Showcase 2025, being held January...Read more
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting the study Median OS of 13.7 months in breast cancer patients with central nervous system (CNS) metastasis treated with the...Read more
SYDNEY, Dec. 11, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development, announced that data from two abstracts will be presented at the San Antonio Breast Cancer Symposium highlighting the activity the Company's lead product candidate, paxalisib, for the potential treatment of immunotherapy-resistant triple negative breast cancer (TNBC) and HER2 positive metastatic breast cancer with active...Read more
Introduces 2025 full year revenue guidance of $180 million to $200 million, a 17% increase in revenue growth over 2024, and core adjusted earnings per diluted share of $6.00 to $6.25 Twelve commercial-stage programs and late-stage pipeline are expected to drive strong revenue growth over the next five years Long-term royalty receipts expected to deliver at least a 22% compound annual growth rate JUPITER, Fla. / Dec 10, 2024 /...Read more
BEDFORD, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference to be held January 13-16, 2025 in...Read more
Clinical Trial and Clinical Pharmacology Data Support Upcoming Enrollment of Omeros’ Zaltenibart Phase 3 Clinical Program in PNH SEATTLE / Dec 10, 2024 / Business Wire / Omeros Corporation (Nasdaq: OMER) today announced that two posters directed to zaltenibart (OMS906), Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement, were presented at the 66th Annual...Read more
Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD, PhD join Cardiovascular Scientific Advisory Board Company nominates abdominal aortic aneurysm as second cardiovascular indication for pacibekitug, expanding development for inflammation-driven cardiovascular disease NEW YORK,...Read more
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECOPYRIGHT ©2023 HEALTH STOCKS HUB